Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.

Bayer's successful trial comes after it previously halted a phase 3 clinical trial testing the effectiveness of the same experimental drug for stroke and systemic embolism prevention in 2023. At the ...

The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during ...

Bayer AG said an experimental stroke-prevention drug showed positive results in a late-stage clinical study, a boost for the ...

Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key ...

Bayer shares surge after its asundexian stroke drug shows positive Phase III results, offering a key boost to its pipeline ...

Investing.com -- Bayer’s (ETR:BAYGN) experimental stroke drug could generate €3 billion in annual sales after successful trial results that Goldman Sachs analyst James Quigley called "transformational ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

The Chinese e-commerce leader said its Qwen artificial-intelligence app drew more than 10 million downloads i ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...